Good Morning @spierf

The general principle to keep in mind is that therapeutic claims must be consistent with the product’s Health Canada approved “Terms of Market Authorization” (TMA). In the Natural Health Product (NHP) realm, monographs such as the Multi-Vitamin/Mineral Supplements Monograph are intended to serve as a guide to industry for the preparation of Product Licence Applications. Once the NNHPD completes its review of the PLA form, the approved components of the form are reflected on the Product Licence. As such, for NHPs, all claims in advertising should be consistent with the Health Canada approved Product Licence corresponding to the particular product in question (as this is the TMA for said product).

Hello @gbrl88 ,
We’ll begin by reiterating that promotion of these products to the public is strictly prohibited. Now onto your question. With regards to HCP advertising, the provisions of the PAAB Code apply to all healthcare products including narcotics and controlled drugs.

The Food and Drugs Act, the Food and Drug Regulations, the Controlled Drugs and Substances Act, and the Narcotic Control Regulations outline Federal requirements pertaining to promotional materials and promotional activities (including sampling). Note that provinces may also impose additional local restrictions pertaining to sampling activities. The Innovative Medicines Canada Code of Ethical Practices also contains standards pertaining to the activity of sampling.
You may have heard that Health Canada has recently amended healthcare product sampling laws. These amendments came into effect on July 1, 2020. But they do NOT impact sampling pertaining to controlled drugs.

Importantly, for opioids (specifically those on Part B of the Opioids list), Health Canada has established Terms and Conditions that must be adhered. This was followed by additional restrictions on marketing of opioids.

Does anyone in this community use additional resources pertaining to the question? If so, sharing is caring! Post them in this thread.